ASCO Guidelines for ICI-Induced Evans Syndrome Management
For ICI-induced Evans syndrome, hold the immune checkpoint inhibitor immediately and initiate prednisone 1 mg/kg/day (range 0.5-2 mg/kg/day) orally for 4 weeks followed by a 4-6 week taper, with IVIG (1 g/kg as a one-time dose) added if rapid platelet recovery is needed. 1
Grading-Based Management Algorithm
The ASCO 2021 guideline addresses Evans syndrome within the context of immune thrombocytopenia (ITP) with concurrent hemolytic anemia (positive direct antigen test), using platelet count as the primary grading criterion 1:
Grade 1 (Platelet count 75 to <100,000/mL)
- Continue ICI with close clinical follow-up and laboratory monitoring
- No specific intervention required at this stage
Grade 2 (Platelet count 50 to <75,000/mL)
- Hold ICI immediately and monitor for improvement
- If not resolved, interrupt treatment until adverse event reverts to Grade 1
- Prednisone 1 mg/kg/day (dosage range 0.5-2 mg/kg/day) orally for 4 weeks
- Taper over 4-6 weeks to the lowest effective dose
- IVIG may be added in conjunction with corticosteroids if more rapid platelet increase is required
Grade 3 (Platelet count 25,000 to <50,000/mL)
- Same management as Grade 2
- Mandatory hematology consultation
- Consider dexamethasone 40 mg daily for 4 days as alternative to prednisone
- IVIG dose: 1 g/kg as a one-time dose if used
Grade 4 (Platelet count <25,000/mL)
- If corticosteroids and/or IVIG unsuccessful, escalate to:
- Rituximab
- Thrombopoietin receptor agonists
- More potent immunosuppression
- Consult American Society of Hematology ITP guidelines for further details 1
Required Workup and Evaluation
The guideline specifies comprehensive evaluation before initiating treatment 1:
- History: Focus on autoimmune disease (personal and family history), lymphocyte-depleting therapy exposure (fludarabine, ATG, steroids, cytotoxic chemotherapy), viral illness history
- Physical examination: Document spleen size
- Laboratory testing:
- CBC with differential, peripheral blood smear, reticulocyte count
- Direct antigen test (Coombs test) to confirm concurrent hemolytic anemia (defining Evans syndrome)
- Infectious disease screening: HIV, HCV, HBV, H. pylori
- Nutritional evaluation
- Bone marrow evaluation: Only if abnormalities in above testing require further diagnostic clarification or concern for aplastic anemia
Clinical Context and Pitfalls
Evans syndrome during ICI therapy is rare but well-documented 2, 3. Two recent case reports demonstrate that onset can occur after prolonged treatment (approximately 11 months in biliary tract cancer patients on durvalumab, and 26 months in a pembrolizumab-treated patient) 2, 3. This delayed presentation underscores the need for ongoing hematologic surveillance throughout ICI therapy, not just during initial treatment cycles.
Critical pitfall: The guideline emphasizes checking the direct antigen test specifically to identify concurrent Evans syndrome rather than isolated ITP 1. This distinction is crucial because Evans syndrome represents a more severe autoimmune phenomenon requiring the same aggressive management approach but with recognition of the dual pathology.
Both case reports confirm that corticosteroids remain the cornerstone of treatment, with gradual symptom improvement observed 2, 3. High-dose pulse corticosteroid therapy may be necessary in refractory cases 3.
ICI Rechallenge Considerations
The guideline does not provide explicit recommendations for ICI rechallenge after Evans syndrome resolution. However, for Grade 1 acquired hemophilia A (a related hematologic irAE), the guideline states to "hold ICPi and discuss resumption with patient only after taking into account the risks and benefits" 1, suggesting a cautious, individualized risk-benefit discussion is appropriate for severe hematologic toxicities.